A#1745 Post-hoc ORAL Surveillance - statin <1/4 on a statin, only 53% h/o ASCVD on statin Incr in LDL was less on Tof

A#1745 Post-hoc ORAL Surveillance - statin <1/4 on a statin, only 53% h/o ASCVD on statin Incr in LDL was less on Tofa pts on statin Among those on b/l statins, there is no incr risk compare to TNFi, esp pts h/o ASCVD If high risk on tofa, statin helps! @RheumNow #ACR24 #ACRBest https://t.co/7MGgUk7tfI